Multicenter analysis of radioactive iodine therapy outcomes after total thyroidectomy for T1-T2 stage papillary thyroid carcinoma with cervical lymph node metastasis in China

医学 甲状腺癌 内科学 比例危险模型 单变量分析 倾向得分匹配 淋巴结 阶段(地层学) 甲状腺癌 甲状腺切除术 甲状腺乳突癌 肿瘤科 颈淋巴结 转移 多元分析 甲状腺 癌症 古生物学 生物
作者
Xinhua Li,Qiuhua Wu,Jie Zhao,Zhiqiang Gui,Jingzhe Xiang,Jie Ming,Tao Huang,Ming‐Ming Jiang,Hao Zhang,Zhihong Wang
出处
期刊:International Journal of Surgery [Wolters Kluwer]
卷期号:111 (10): 6931-6941
标识
DOI:10.1097/js9.0000000000002838
摘要

Background: The optimal approach for radioactive iodine (RAI) therapy of T1-T2 stage papillary thyroid carcinoma (PTC) with cervical lymph node metastasis following total thyroidectomy (TT) remains unclear. This study aimed to provide individualized RAI therapy recommendations regarding the type of therapy, frequency, dosage, and interval after surgery based on treatment response. Methods: This multicenter study enrolled 408 T1-T2 PTC patients with cervical lymph node metastasis who underwent TT. Data were derived from a collaborative initiative involving major thyroid cancer centers across China, which prospectively standardized clinical data collection for differentiated thyroid carcinoma between 2015 and 2022. Propensity score matching (PSM) was employed to balance baseline characteristics between the TT + RAI therapy group and the TT group. Comparisons of clinical-pathological parameters were performed before and after PSM. Primary endpoints included structural incomplete response (SIR) and biochemical incomplete response (BIR). Variables with statistical significance ( P < 0.05) or clinical relevance in univariate analysis were subjected to multivariate Cox regression. Recurrence-free survival (RFS) was analyzed using Kaplan-Meier methods with log-rank testing. Results: Among the cohort, 280 patients (68.6%) underwent RAI therapy following TT. During a median follow-up of 76.8 months, 41 patients (10.0%) demonstrated incomplete responses, comprising SIR ( n = 18) and BIR ( n = 23). After PSM, 28 patients (12.0%) exhibited incomplete responses (SIR: 13 and BIR: 15). Comparative analysis revealed no statistically significant differences in SIR/BIR rates between the TT + RAI cohort and TT group ( P > 0.05). Cox regression analysis identified the lymph node metastasis ratio as an independent predictor of SIR development (hazard ratio [HR] 5.130; 95% confidence interval [CI]: 1.194–22.051; P = 0.028). Kaplan-Meier survival curves demonstrated comparable outcomes between groups for both structural recurrence-free survival (RFS structural ) and biochemical recurrence-free survival (RFS biochemical ). Conclusion: In T1-T2 PTC with cervical lymph node metastasis, no significant difference was observed in the SIR or BIR between TT + RAI and TT groups. The frequency, dose, and interval of RAI therapy after surgery were not considered risk factors for SIR or BIR.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
香蕉觅云的应助被包容清炎采纳,获得10
刚刚
十六完成签到 ,获得积分10
2秒前
虚幻亦竹发布了新的文献求助10
2秒前
852的应助被郭娅楠采纳,获得10
2秒前
SunFlower完成签到,获得积分10
2秒前
慕青的应助被小螃蟹大大王采纳,获得10
2秒前
啄米鸡完成签到,获得积分10
3秒前
朴实归尘发布了新的文献求助30
3秒前
4秒前
F二次方的应助被hachimeki采纳,获得50
4秒前
yang发布了新的文献求助10
5秒前
科研通AI6.4的应助被热情曲奇采纳,获得10
5秒前
6秒前
杨胖胖完成签到,获得积分10
6秒前
7秒前
浮云发布了新的文献求助10
8秒前
8秒前
科研通AI2S的应助被院士徐若木采纳,获得10
8秒前
望常桑完成签到,获得积分10
8秒前
jiacooo完成签到 ,获得积分10
9秒前
Ying发布了新的文献求助10
9秒前
10秒前
李健的小迷弟的应助被杨胖胖采纳,获得10
10秒前
lsy完成签到,获得积分10
10秒前
tang发布了新的文献求助100
11秒前
虚幻亦竹完成签到,获得积分10
11秒前
传奇3的应助被mouse采纳,获得10
11秒前
余香的应助被Lu采纳,获得10
12秒前
12秒前
13秒前
13秒前
14秒前
14秒前
郭娅楠发布了新的文献求助10
14秒前
superman发布了新的文献求助10
15秒前
PYPYPY完成签到,获得积分10
15秒前
15秒前
海一鸣完成签到,获得积分10
15秒前
16秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184267
求助须知:如何正确求助?哪些是违规求助? 9573323
关于积分的说明 21830790
捐赠科研通 7781314
什么是DOI,文献DOI怎么找? 3434307
关于科研通互助平台的介绍 2558389
邀请新用户注册赠送积分活动 2480817